pharma · Hepatitis B · Mixed Dyslipidemia · ARWR
Arrowhead Pharmaceuticals Ireland
Arrowhead Pharmaceuticals Ireland Limited
Arrowhead Pharmaceuticals is a pharma organization headquartered in Pasadena, USA. It trades on NYSE under ticker ARWR. Primary therapeutic focus areas include Hepatitis B, Mixed Dyslipidemia, Severe Hypertriglyceridemia
Company details
- Status
- Public
- HQ
- 177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US
- Employees
- 746
- Programs
- 63
- Drugs
- 34
- Patents
- 126
Quick answer
Arrowhead Pharmaceuticals is a pharma organization headquartered in Pasadena, USA. It trades on NYSE under ticker ARWR. Primary therapeutic focus areas include Hepatitis B, Mixed Dyslipidemia, Severe Hypertriglyceridemia, Severe hypertriglyceridemia (SHTG), Hypertriglyceridemia. NovaPharmaNews links 63 clinical program(s), 2 drug profile(s), and 126 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (30), phase 3 (18), phase 1 (13).
Company snapshot
Arrowhead Pharmaceuticals Ireland maintains 63 tracked programs across Hepatitis B, Mixed Dyslipidemia, Severe Hypertriglyceridemia, Severe hypertriglyceridemia (SHTG), Hypertriglyceridemia, Alpha 1-Antitrypsin Deficiency, Homozygous Familial Hypercholesterolemia, Asthma, Chronic Hepatitis B, Obesity, Dyslipidemias, Inflammatory Lung Disease. Momentum score: 28/100 (30-day delta: n/a). Public regi
- 2 approved product(s) across US/EU regulatory metadata.
- 63 active pipeline program(s) linked via ClinicalTrials.gov.
- 126 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Arrowhead Pharmaceuticals Ireland. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
Arrowhead Pharmaceuticals to Participate in Key June 2026 Industry Events
- trial_data
Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting
Recent coverage
Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting
Arrowhead Pharmaceuticals has presented new positive clinical data for its cardiometabolic disorder program at the 94th European A meeting. This development could significantly impact the competitive landscape and presents potential opportunities for pharmaceutical business development teams.
Arrowhead Pharmaceuticals to Participate in Key June 2026 Industry Events
Arrowhead Pharmaceuticals is set to participate in several key industry events throughout June 2026. These appearances provide a crucial opportunity for analysts, strategy, and business development teams to gain insights into the company's pipeline advancements and strategic direction.
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Arrowhead Pharmaceuticals Ireland.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Arrowhead Pharmaceuticals Ireland.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 — Phase 1
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Arrowhead Pharmaceuticals Ireland?
-
Is Arrowhead Pharmaceuticals Ireland publicly traded?
-
What drugs does Arrowhead Pharmaceuticals Ireland develop or market?
-
What are the latest developments for Arrowhead Pharmaceuticals Ireland?
-
What therapeutic areas does Arrowhead Pharmaceuticals Ireland focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.